Skip to main content

Phase 1 Neurology Deal Benchmarks

Median Upfront
$112M
Range: $45M - $185M
Total Deal Value
$1.6B
Range: $811M - $2.4B
Royalty Rate
7.4% - 14.8%
Tiered up to 18.8%
Dev Milestones
$755M
Range: $383M - $1.1B
Model Your Deal

Market Analysis

Phase 1 neurology licensing deals carry a median total deal value of $1.6B, with upfront payments ranging from $45M to $185M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 7% to upfront and 93% to milestones.

The neurology landscape at the phase 1 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $755M, regulatory milestones contribute $453M, and commercial milestones reach $302M. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for phase 1 neurology deals range from 7.4% to 14.8% at the base tier, with high-tier escalation to 18.8%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1 neurology deals?
Phase 1 neurology deals average $112M in upfront payments, ranging from $45M to $185M. The upfront allocation of 7% of total deal value reflects the clinical stage risk profile.
How are phase 1 neurology deal milestones structured?
Milestones account for approximately 93% of total deal value. Development milestones ($755M) represent the largest component, followed by commercial milestones ($302M) and regulatory milestones ($453M).
What royalty rates are typical for phase 1 neurology licensing?
Base royalty rates range from 7.4% to 14.8%, with tiered escalation to 11.4%-18.8% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Preclinical Neurology Deals

View

Phase 1/2 Neurology Deals

View

Phase 1 Oncology Deals

View

Phase 1 Immunology & Autoimmune Deals

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included